Bibliografía del artículo
1. Liu Y, Yan R, Song A, Niu X, Cao C, Wei J, et al. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy. Am J Hypertens 27(2):268-78, 2014.
2. Escobar C, Barrios V. An evaluation of the latest evidence relating to renin-angiotensin system inhibitors. Expert Opin Drug Metab Toxicol 9(7):847-58, 2013.
3. Taylor AA, Ragbir S. Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension. Patient Prefer Adherence 6:555-63, 2012.
4. Volman S, Benitez F, Cedenio H, Giorgi M, Jaramillo N, Molina N, et al. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS). Ther Adv Cardiovasc Dis 7(4):189-96, 2013.
5. Balcarek J, Sevá PB, Bryson C, Azizi M, Ménard J, Garrelds I, et al. Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension 63(5):942-50, 2014.
6. Sullivan J, Keefe D, Zhou Y, Satlin L, Fang H, Yan J. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clin Pediatr (Phila) 52(7):599-607, 2013.
7. St Peter W, Odum L, Whaley-Connell A. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy 33(5):496-514, 2013.
8. Fogari R, Mugellini A, Zoppi A, Preti P, Maffioli P, Perrone T, et al. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. Expert Opin Pharmacother 14(4):371-84, 2013.
9. Lee K, Chan C, Yang Y, Hsieh Y, Huang Y, Lin H. Aliskiren attenuates chronic carbon tetrachloride-induced liver injury in mice. Eur J Clin Invest 42(12):1261-71, 2012.
10. Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Verdecchia P. Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opin Drug Saf 11(4):659-70, 2012.
11. Sadeghpour A, Rappolt M, Ntountaniotis D, Chatzigeorgiou P, Viras K, Megariotis G, et al. Comparative study of interactions of aliskiren and AT1 receptor antagonists with lipid bilayers. Biochim Biophys Acta 1848(4):984-94, 2015.
12. Uger T. The role of the renin-angiotensin system in the development of cardiovascular disease. The American Journal of Cardiology 89(2A), 2002.
13. Bonanni L, Dalla VM. Oral renin inhibitors in clinical practice: a perspective review. Ther Adv Chronic Dis 3(4):173-81, 2012.
14. Dhakarwal P, Agrawal V, Kumar A, Goli K, Agrawal V. Update on role of direct renin inhibitor in diabetic kidney disease. Ren Fail 36(6):963-9, 2014.
15. Saraswat M, Addepalli V, Jain M, Pawar V, Patel R. Renoprotective activity of aliskiren, a renin inhibitor in cyclosporine A induced hypertensive nephropathy in dTG mice. Pharmacol Rep 66(1):62-7, 2014.
16. Riccioni G. The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient. The Adv Endocrinol Metab 4(5):139-145, 2013.
17. Hoffmann P, Beckman D, McLean L, Yan J. Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression. Toxicol Appl Pharmacol 275(1):36-43, 2014.
18. Khadzhynov D, Slowinski T, Lieker I, Neumayer H, Albrecht D, Streefkerk H, et al. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis. Clin Pharmacokinet 51(10):661-9, 2012.
19. Tocci G, Aimo G, Caputo D, De Matteis C, Di Napoli T, Granatelli A, et al. An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy. High Blood Press Cardiovasc Prev 19(2):73-83, 2012.
20. Liu Y, Chen K, Kou X, Han Y, Zhou L, Zeng C. Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. PLoS One 8(7), 2013.
21. Szeto C, Kwan B, Chow K, Leung C, Li P. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy: a randomized cross-over study. PLoS One 8(5), 2013.